Efficacy

Efficacy of Sotyktu (deucravacitinib) in Treating Psoriasis

Sotyktu, with the active ingredient deucravacitinib, is a novel oral medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. As a selective tyrosine kinase 2 (TYK2) inhibitor, Sotyktu works by modulating the immune response that contributes to the inflammation and plaque formation characteristic of psoriasis. Clinical trials have demonstrated that Sotyktu can lead to significant skin clearance. In the pivotal Phase 3 POETYK PSO-1 and PSO-2 trials, patients treated with Sotyktu showed a marked reduction in the Psoriasis Area and Severity Index (PASI) scores, which is a measure of the severity of psoriasis plaques, compared to those who received placebo.

The efficacy of Sotyktu was sustained over time, with a significant proportion of patients maintaining their PASI 75 response (75% reduction in PASI score) through 52 weeks of treatment. Moreover, many patients achieved a PASI 90 or PASI 100 response, indicating near-complete or complete clearance of skin lesions. The convenience of an oral administration route makes Sotyktu a valuable addition to the therapeutic arsenal for psoriasis, providing an alternative to injectable biologic treatments.

Efficacy of Bimzelx (bimekizumab-bkzx) in Treating Psoriasis

Bimzelx, with the active substance bimekizumab-bkzx, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx is a monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F, two key cytokines involved in the inflammatory process of psoriasis. Clinical studies, including the BE VIVID, BE READY, and BE SURE trials, have shown that Bimzelx can produce rapid and extensive skin clearance.

In these trials, a significant majority of patients treated with Bimzelx achieved PASI 90 and PASI 100 responses, indicating a high level of disease improvement. The onset of action was rapid, with some patients experiencing significant improvements as early as week 4. The efficacy of Bimzelx was maintained over a long-term period, with durable responses observed up to one year. The administration of Bimzelx is via subcutaneous injection, which may be preferred by some patients over oral medications or more frequent dosing schedules.